Literature DB >> 10638697

Effects of hemoglobin-based oxygen-carrying solutions in anesthetized rats with acute ischemic renal failure.

W Lieberthal1, R Fuhro, C Andry, C R Valeri.   

Abstract

The effects of three hemoglobin solutions were compared with those of iso-oncotic human serum albumin in rats with ischemic renal failure and sham-operated controls. Unmodified and alpha-alpha cross-linked hemoglobins both increase mean arterial pressure and systemic vascular resistance and reduce cardiac output substantially and to a comparable extent. In contrast, omicron-raffinose cross-linked hemoglobin has no deleterious effect on any of these parameters. In sham-operated rats unmodified hemoglobin reduces the glomerular filtration rate (GFR) by approximately 30%, whereas neither of the two cross-linked hemoglobins has any adverse effect on GFR in this group. None of the three hemoglobin solutions exacerbated the degree to which GFR was reduced by ischemia-reperfusion injury. Also, the degree of tubular necrosis induced by ischemia-reperfusion injury was also comparable in all groups. We conclude the following: (1) omicron-raffinose cross-linking, but not alpha-alpha cross-linking, ameliorates the effects of unmodified hemoglobin on vascular resistance and cardiac output; (2) both forms of cross-linking reduce the nephrotoxicity exhibited by unmodified hemoglobin in sham-operated rats; and (3) none of the hemoglobin solutions exacerbate renal injury induced by ischemia-reperfusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10638697     DOI: 10.1016/s0022-2143(00)70023-0

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  2 in total

1.  Significance of hemolysis on extracorporeal life support after cardiac surgery in children.

Authors:  Rasheed Gbadegesin; Shuang Zhao; John Charpie; Patrick D Brophy; William E Smoyer; Jen-Jar Lin
Journal:  Pediatr Nephrol       Date:  2008-11-12       Impact factor: 3.714

Review 2.  Hemoglobin-based oxygen carriers.

Authors:  A Gerson Greenburg; Hae Won Kim
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.